We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

Back to rankings

37 hedge funds and large institutions have $6.45M invested in Neos Therapeutics, Inc in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

491% more call options, than puts

Call options by funds: $65K | Put options by funds: $11K

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

10% less funds holding

Funds holding: 41 → 37 (-4)

26% less capital invested

Capital invested by funds: $8.74M → $6.45M (-$2.29M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
37
Holders Change
-4
Holders Change %
-9.76%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
7
Closed
10
Calls
$65K
Puts
$11K
Net Calls
+$54K
Net Calls Change
+$59K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$357K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$151K
3
Renaissance Technologies
Renaissance Technologies
New York
+$71.5K
4
VF
Virtu Financial
New York
+$10.6K
5
UBS Group
UBS Group
Switzerland
+$7.36K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$2.44M
2
Goldman Sachs
Goldman Sachs
New York
-$1.42M
3
BCM
Bridgeway Capital Management
Texas
-$46.3K
4
TRCT
Tower Research Capital (TRC)
New York
-$13K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$12.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Stonepine Capital Management
Oregon
$3.1M +$357K +578,458 +13%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.06M -$12.9K -20,805 -1%
Renaissance Technologies
3
Renaissance Technologies
New York
$673K +$71.5K +115,783 +12%
BlackRock
4
BlackRock
New York
$251K +$1.26K +2,040 +0.5%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$212K – – –
Goldman Sachs
6
Goldman Sachs
New York
$211K -$1.42M -2,294,397 -87%
DM
7
Deerfield Management
New York
$201K – – –
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$153K +$151K +245,105 New
BCM
9
Bridgeway Capital Management
Texas
$143K -$46.3K -75,000 -25%
Northern Trust
10
Northern Trust
Illinois
$81K -$2.81K -4,549 -3%
BGIM
11
Brandywine Global Investment Management
Pennsylvania
$76K +$1.11K +1,801 +1%
HAIM
12
Hunter Associates Investment Management
Pennsylvania
$62K – – –
SW
13
SlateStone Wealth
Florida
$39K – – –
VF
14
Virtu Financial
New York
$26K +$10.6K +17,204 +71%
California Public Employees Retirement System
15
California Public Employees Retirement System
California
$24K – – –
ACM
16
Allred Capital Management
Texas
$15K – – –
SCM
17
Southport Capital Management
Tennessee
$15K – – –
State Street
18
State Street
Massachusetts
$15K – – –
BA
19
Bridge Advisory
California
$15K +$14.6K +23,564 New
Charles Schwab
20
Charles Schwab
California
$14K – – –
CIBC Private Wealth Group
21
CIBC Private Wealth Group
Georgia
$10K – – –
Bank of New York Mellon
22
Bank of New York Mellon
New York
$9K – – –
Commonwealth Equity Services
23
Commonwealth Equity Services
Massachusetts
$8K -$309 -500 -4%
RJA
24
Raymond James & Associates
Florida
$7K – – –
UBS Group
25
UBS Group
Switzerland
$7K +$7.36K +11,916 New
1
2

NEOS Hedge Fund Activity: Q4 2020 in Review

37 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q4 2020, worth a combined $6.45M — down 26% from $8.74M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NEOS and 7 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 7 added.

The largest buyer was Stonepine Capital Management, adding an estimated $357K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $2.44M sold.

  • 37 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q4 2020, down from 41 in Q3 2020.
  • Funds reported $6.45M of Neos Therapeutics, Inc stock for Q4 2020, down 26% quarter-over-quarter.
  • 7 funds opened new Neos Therapeutics, Inc positions in Q4 2020 and 10 closed out, a net change of -3 holders.
  • The largest Neos Therapeutics, Inc buyer in Q4 2020 was Stonepine Capital Management, an estimated $357K added.
  • The largest Neos Therapeutics, Inc seller in Q4 2020 was Nantahala Capital Management, an estimated $2.44M sold.

Based on aggregated 13F filings for Q4 2020.